BioNotebook: Ambit, Xencor, Soligenix, Ampio
This article was originally published in Scrip
Executive Summary
Ambit stock drops on no accelerated filing for quizartinib; Xencor prices IPO, rises in first day; Soligenix starts Phase II orBec study; and Ampio updates Phase III Ampion status.